FDA Grants Breakthrough Device Designation to AutoGenomics’ INFINITI® Neural Response Panel for the Identification of the Risk of Opioid Dependency
Journal of Anesthesia & Pain Medicine · 2018
DOI: 10.33140/japm.03.03.05 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Anesthesia & Pain Medicine, 2018.
Abstract (Originalsprache)
June 04, 2018 AutoGenomics, Inc., based in Carlsbad, CA, announced that its INFINITI® Neural Response Panel has been granted designation as a Breakthrough Device by the US Food and Drug Administration (FDA). The INFINITI® Neural Response Panel is a qualitative in vitro diagnostic test for the identification of patients who may be at risk for opioid dependency. The Panel is designed to identify 16 genetic mutations involved in the brain reward pathways that are associated with increased risk of opioid use disorder, and is intended for use by physicians as an aid for safe and effective pain management
Zitieren
APA
(2018). FDA Grants Breakthrough Device Designation to AutoGenomics’ INFINITI® Neural Response Panel for the Identification of the Risk of Opioid Dependency. Journal of Anesthesia & Pain Medicine. https://doi.org/10.33140/japm.03.03.05
Vancouver
FDA Grants Breakthrough Device Designation to AutoGenomics’ INFINITI® Neural Response Panel for the Identification of the Risk of Opioid Dependency. Journal of Anesthesia & Pain Medicine. 2018. doi:10.33140/japm.03.03.05
BibTeX
@article{euvimed2018,
title = {FDA Grants Breakthrough Device Designation to AutoGenomics’ INFINITI® Neural Response Panel for the Identification of the Risk of Opioid Dependency},
journal = {Journal of Anesthesia & Pain Medicine},
year = {2018},
doi = {10.33140/japm.03.03.05}
}
EUVIMED